LEO Pharma US

Happy International Women’s Day! At LEO Pharma, our dedication to gender equality and women’s empowerment extends far beyond today. It is part of our broader goal of sustainable development, aiming to leave a legacy of innovation, inclusivity, and responsible impact for future generations. #LEOPharma #IWD2025 #AccelerateAction

Today LEO Pharma announces Robert Spurr has been appointed the new EVP of Region North America and CEO & President of LEO Pharma Inc. US, effective January 29, 2025. Robert succeeds Brian Hilberdink, who will be leaving LEO Pharma to pursue an external opportunity. “Robert’s track record and leadership qualities make him ideally suited to his new role. Over the last 18 months I have been truly impressed by his key contributions to the US affiliate. I would like to congratulate him on his appointment and welcome him as a member of LEO Pharma’s Global Leadership Team. His contributions will be instrumental in further strengthening our growth trajectory in North America.” Christophe Bourdon CEO, LEO Pharma #Leadership #LEOPharma #Dermatology

We’re partnering with Gilead Sciences to accelerate the development and commercialization of LEO Pharma’s small molecule oral STAT6 programs for the potential treatment of patients with inflammatory diseases. STAT6 is the specific transcription factor required for IL-4 and IL-13 cytokine signaling, which are clinically validated targets for Th2-mediated inflammatory conditions such as atopic dermatitis, asthma, and COPD, amongst many others. Targeting STAT6 has shown potential preclinically to treat a broad population of patients and may provide an oral alternative to those currently treated with injectable biologics. “STAT6 holds potential for treating various inflammatory diseases, including outside dermatology. This strategic partnership with Gilead will enable us to accelerate the development of the STAT6 program and maximize its potential in dermatology and beyond,” said Christophe Bourdon, CEO of LEO Pharma. Learn more https://brnw.ch/21wPZx3 #LEOPharma #NEWS #PressRelease #STAT6 #Innovation

We're proud to help raise awareness of the drug disposal options available nationwide. DEA take back day is October 26. Learn how to prepare, what will be collected, and how to safely store your medicine until the event at MyOldMeds.com/blog. #ppswg #myoldmeds #safestorage #safedisposal?

We were thrilled to attend the?#EADVCongress and showcase our extensive data and expertise across several skin conditions. Our onsite team acquired valuable insights that will help further our mission of advancing the standard of care in medical dermatology. #DermatologyBeyondTheSkin

#PRESS LEO Pharma presents late-breaker highlighting real-world data in #AtopicDermatitis. That makes 5 late-breaker presentations that LEO Pharma has presented this week! In addition, 23 other scientific posters were also presented for a range of skin conditions, truly reinforcing our dedication to addressing the diverse needs of those living with skin conditions.?

#PRESS LEO Pharma releases new late-breaker data for #ChronicHandEczema. We look forward to showcasing the rest of our scientific program in the coming days at #EADVCongress. #DermatologyBeyondTheSkin

Today, we commemorate Juneteenth, a powerful reminder of the ongoing struggle for equality, justice, and freedom. At LEO Pharma, we embrace diversity and stand for inclusivity. Let's reflect on progress made and together make a positive impact on the future.

Today, we commemorate Juneteenth, a powerful reminder of the ongoing struggle for equality, justice, and freedom. At LEO Pharma, we embrace diversity and stand for inclusivity. Let's reflect on progress made and together make a positive impact on the future.

#PRESS LEO Pharma releases late-breaker for moderate to severe #CongenitalIchthyosis at #AAD2024 https://lnkd.in/euc5YX7X